

OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Diep Tuan Tu</u> <hr/> (Last) (First) (Middle) <u>11250 EL CAMINO REAL</u> <u>SUITE 100</u> <hr/> (Street) <u>SAN DIEGO CA 92130</u> <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>03/04/2024</u>	3. Issuer Name and Ticker or Trading Symbol <u>Skye Bioscience, Inc. [ SKYE ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <p style="text-align: center;"><b>Chief Operating Officer</b></p>	5. If Amendment, Date of Original Filed (Month/Day/Year) <u>02/29/2024</u> <hr/> 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	72,833 <sup>(1)</sup>	D	
Common Stock	4,000 <sup>(2)</sup>	D	

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (Right to Buy)	(3)	10/05/2030	Common Stock	8,000	11.25	D	
Stock Option (Right to Buy)	(4)	12/14/2031	Common Stock	7,080	14.5	D	
Stock Option (Right to Buy)	(5)	09/29/2033	Common Stock	22,021	3.5	D	
Stock Option (Right to Buy)	(6)	11/06/2033	Common Stock	9,194	3.5	D	

**Explanation of Responses:**

- The restricted stock unit ("RSU") award was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. Represents RSU awards for up to 72,833 shares that vest on the following performance milestones: 25% vests upon achieving a market cap of \$125M, an additional 25% vests upon achieving a market cap of \$250M, an additional 25% vests upon achieving a market cap of \$400M, an additional 25% vest at an exit of \$500M or greater; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs. Upon a change in control of the Issuer, 100% of the RSUs will become fully vested.
- The restricted stock unit ("RSU") award was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. Represents a RSU award that vests in three equal annual installments commencing on the first anniversary of the grant date, December 14, 2021. Upon a change in control of the Issuer, all of the RSUs will vest in full.
- The stock option was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. The stock option vests 10% on the grant date, October 5, 2020, and the remaining 90% of the stock option will vest in equal semi-annual installments over four annual periods. Upon a change in control of the Issuer, 100% of the stock option will become fully vested.
- The stock option was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. The stock option vests 25% on the one year anniversary of the grant date, December 14, 2021, and 1/48th monthly thereafter. Upon a change in control of the Issuer, 100% of the stock option will become fully vested.
- The stock option was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested.
- The stock option was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested.

**Remarks:**

/s/ Punit S. Dhillon, as Attorney-in-Fact      04/02/2026

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.